10/552982 JC05Rec'd PCT/PTO 12 OCT 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Melotto, S. et al.						
Serial No.:	To Be Assigned	Group Art Unit:					
File Date:	Concurrently Herewith	Examiner:					
For:	PHENYL)-4-(S)-((8AS YL)-PIPERIDINE-1-CAF	COMBINATIONS OF PAROXETINE AND 2-(R)-(4-FLUORO-2-METHYL-PHENYL)-4-(S)-((8AS)-6-OXO-HEXAHYDRO-PYRROLO'1,2-A!-PYRAZIN-2-YL)-PIPERIDINE-1-CARBOXYLIC ACID'1-(R)-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL!-METHYLAMIDE F. TREATMT. OF DEPRESSION/ANXIETY					
Director of the U.S. P.O. Box 1450 Alexandria, VA 223	Patent and Trademark Office						
	INFORMATION DI	SCLOSURE STATEMENT					
Applicants requ Examiner and officia	est that the references identified lly made of record in accordance	on Form PTO-1449 appended hereto be considered by the with the provisions of 37 CFR 1.97					
[] Copies of th [X] A copy of th PCT/EP04/0 are listed on	004121 is submitted herewith. A	hich issued on International Application No. Il of the publications cited in the International Search Report d Applicants understand that copies have been supplied to the					
fili app occ OR [] Th of	ng date of the above application olication or before the mailing daturs last. 37 CFR 1.97(b). e Information Disclosure State	ent submitted herewith is being filed within three months of the or date of entry into the national stage of an international stee of a first Office action on the merits, whichever event submitted herewith is being filed before the mailing filing of a Request For Continued Examination under 37)).					
filing dan inter event o	ate of the above application or t						
Stateme	ent was cited in a communication	n of information contained in this Information Disclosure in from a foreign patent office in a counterpart foreign prior to the filing of this statement.					
	nt elects the option to pay the fee re Statement under § 1.97(c) (\$1	set forth in 37 CFR 1.17(p) for submission of an Information 80.00).					

The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International

C. []

Publication No.

JC05 Rec'd PCT/PTO 12 OCT 2005

10/552982

In accordance with the requirements of 37 CFR 1.97(d):

	Applicant hereby certifies that each item of information contained in this Information Disclosure
	Statement was cited in a communication from a foreign patent office in a counterpart foreign
	application not more than three months prior to the filing of this statement.

- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,

Lorie Ann Morgan Registration No. 38,181

Date: /2 Oct 2005
GlaxoSmithKline
Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8222 Facsimile: (919) 483-7988

JC05 Rec'd PCT/PTO 12 OCT 2005

======================================	40	SERIAL NO.		To Be As	To Be Assigned			
FORM PTO-1449				FILING DATE		Concurre	Concurrently Herewith	
INFORMATION DISCLOSURE STATEMENT				ADDITIONT		Melotto e	Melotto et al.	
			GROUP IN		BEE	1552982		
				EXAMINER 20		1776	1 22C 40C	
			ATTORNEY D	OCKET NO.	PB60212-	PB60212-3USW		
		IIS PA	TENT D	OCUMENTS				
		1	1				Filing Date	
Examiner	Patent	Issue Date	Name		Class	Subclass	If Appropriate	
Initials	Number	15520						
	US 2003/144270	July 31, 2003	Laci et al.					
	US 2002/123491	Sept. 5, 2003	Xiao et al.					
	US 2003/064980	Apr. 3, 2003	Xiao et al.					
	US 2004/014770	Jan. 22, 2004	Elvira et al.					
	03 2004/014770	Jan. 22, 2001	Elvila et al.					
		+	1					
		 	1		1			
		Cor	ntinue on	page				
		FOREIGN	PATEN	T DOCUMENTS				
·	Document	Publication	1711211				Translation	
	Number	Date		Country	Class	Subclass	Yes No	
	WO 02/10141	Feb. 7, 2002	WIPO					
	WO 02/10141 WO 01/44200	June 21, 2001	WIPO					
 	WO 03/066635	Aug. 14, 2003	WIPO					
<u> </u>	WO 03/000033	Aug. 14, 2005						
								
								
<u> </u>								
1 -		Co	ntinue on	page				
	OTHER DOCUM	FNTS (Includin	σ Author	Title, Journal-I	ate. Page Nun	ber, Etc.)		
	OTHER DOCUM	Elvio (meladia	<u> </u>	,	, <u>a</u>			
 								
 								
			· ·					
					-	,		
 								
1								
	 							
 	 							
 								
	 	,						
								
			ontinue o	n page	-			
EVANINED			Olithiac O	Ի8	DATE	CONSIDER	ED	
EXAMINER DATE CONSIDERE								
EVAMINED.	Initial if citation conside	ered whether or r	ot citation	n is in conformanc	e with MPEP 8	609; Draw li	ne through	
EXAMINER:	n conformance and not of	onsidered Inclu	de conv o	f this form with ne	ext communicat	ion to the apr	olicant.	
citation if not i	ii comoi mance and not c	onsidered. Inclu	ac copy o	10 ** 10				